These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 18398148)

  • 1. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Gruenberger B; Tamandl D; Schueller J; Scheithauer W; Zielinski C; Herbst F; Gruenberger T
    J Clin Oncol; 2008 Apr; 26(11):1830-5. PubMed ID: 18398148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
    Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
    Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
    BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
    Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.
    Abdalla EK; Eng C; Madary A; Vauthey JN;
    Clin Colorectal Cancer; 2006 Mar; 5(6):436-9. PubMed ID: 16635283
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Doi T; Boku N; Kato K; Komatsu Y; Yamaguchi K; Muro K; Hamamoto Y; Sato A; Koizumi W; Mizunuma N; Takiuchi H
    Jpn J Clin Oncol; 2010 Oct; 40(10):913-20. PubMed ID: 20462981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.
    Alberts SR; Roh MS; Mahoney MR; O'Connell MJ; Nagorney DM; Wagman L; Smyrk TC; Weiland TL; Lai LL; Schwarz RE; Molina R; Dentchev T; Bolton JS
    J Clin Oncol; 2010 Feb; 28(5):853-8. PubMed ID: 20048179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
    Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
    Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection.
    Dewdney A; Cunningham D; Barbachano Y; Chau I
    Br J Cancer; 2012 May; 106(11):1718-21. PubMed ID: 22531628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
    Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
    Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant therapy with bevacizumab.
    Gruenberger T; Gruenberger B; Scheithauer W
    J Clin Oncol; 2006 Jun; 24(16):2592-3; author reply 2593-4. PubMed ID: 16735714
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Saltz LB; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Cassidy J
    J Clin Oncol; 2008 Apr; 26(12):2013-9. PubMed ID: 18421054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
    Czito BG; Bendell JC; Willett CG; Morse MA; Blobe GC; Tyler DS; Thomas J; Ludwig KA; Mantyh CR; Ashton J; Yu D; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):472-8. PubMed ID: 17498568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204.
    Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB
    Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
    Gruenberger B; Scheithauer W; Punzengruber R; Zielinski C; Tamandl D; Gruenberger T
    BMC Cancer; 2008 Apr; 8():120. PubMed ID: 18439246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
    Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC
    Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
    van Dijk TH; Tamas K; Beukema JC; Beets GL; Gelderblom AJ; de Jong KP; Nagtegaal ID; Rutten HJ; van de Velde CJ; Wiggers T; Hospers GA; Havenga K
    Ann Oncol; 2013 Jul; 24(7):1762-1769. PubMed ID: 23524865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.